J Korean Soc Virol.
1999 Jun;29(2):55-64.
A Field Efficacy Trial of Inactivated Hantaan Virus Vaccine (Hantavax(TM)) Against Hemorrhagic Fever with Renal Syndrome (HFRS) in the Endemic Areas of Yugoslavia from 1996 to 1998
- Affiliations
-
- 1WHO Collaborating Center for Virus Reference and Research (Hantaviruses).
- 2Asan Institute for Life Sciences.
- 3Institute of Immunology and Virology "Torlak", Yugoslavia.
- 4Central Research Institute, Korea Green Cross Co.
- 5Department of Internal Medicine, College of Medicine, Korea University.
- 6Department of Preventive Medicine, College of Medicine, Korea University.
Abstract
- In Yugoslavia, homorrhagic fever with renal syndrome (HFRS) is one of the important national health problem, but no vaccine has been used to prevent HFRS. Since first HFRS case in 1952, sporadic cases of HFRS occurred every year and over 4,000 registered cases with 1~16% mortality so far. We performed a prospective, randomized double-blind placebo-controlled trial to evaluate the effectiveness of Hantavax(TM) against HFRS in 3,900 healthy adults living in the endemic areas of Yugoslavia. 1,900 people were given 0.5 ml of Hantavax subcutaneously twice at one month interval and a booster shot at one year after. For controls other 2,000 healthy people were given 0.5 ml of physiolosical saline as a placebo. We investigated HFRS cases in both the vaccinated and nonvaccinated groups by monitoring the program for patient registration in the areas from 1996 to 1998, and the effect of vaccine was analyzed epidemiologically No confirmed case of HFRS was observed among 1,900 Hantavax vaccinees, while 20 confirmed cases were observed among 2,000 nonvaccinated control group. There were no remarkable side effects among the vaccinees either locally or in general after inoculation of the vaccine. The Hantavax vaccine showed statistically significant protective efficacy against HFRS among Yugoslavian people.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Identification of G1, G2 and N protein of Hantaan virus in an inactivated HFRS vaccine
- Hemorrhagic Fever with Renal Syndrome
- The influence of vaccination on the clinical features of hemorrhagic fever with renal syndrome in the last 5 years
- Effectiveness of inactivated hantavirus vaccine on the disease severity of hemorrhagic fever with renal syndrome
- Safety and immunogenicity of a inactivated hemorrhagic fever with renal syndrome vaccine(Hantaan virus vaccine) in children: clinical study of dose regimen
